• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

    171.88 +0.39 (+0.23%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 791,631
    Open 173.00
    Bid (Size) 171.78 (500)
    Ask (Size) 171.88 (200)
    Prev. Close 171.49
    Today's Range 170.30 - 176.00
    52wk Range 79.19 - 184.40
    Shares Outstanding 47,190,970
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
    As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric... 
    Via MarketMinute
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill

    Performance

    YTD
    -3.8%
    -3.8%
    1 Month
    +16.5%
    +16.5%
    3 Month
    +43.3%
    +43.3%
    6 Month
    +59.9%
    +59.9%
    1 Year
    +101.9%
    +101.9%

    More News

    Read More
    News headline image
    Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗
    Via The Motley Fool
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
    Via Benzinga
    News headline image
    Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗
    Via Stocktwits
    News headline image
    Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
    Via The Motley Fool
    News headline image
    Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
    Via MarketMinute
    Topics Artificial Intelligence Economy Emissions
    News headline image
    Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    2 Monster Stocks in the Making ↗
    Via The Motley Fool
    News headline image
    Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
    Via Chartmill
    News headline image
    Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗
    Via Benzinga
    News headline image
    Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗
    Via The Motley Fool
    News headline image
    Pharma Tariffs Back In Spotlight On New Trump Threat ↗
    Via Investor's Business Daily
    Topics ETFs Government World Trade
    News headline image
    Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
    Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
    The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
    What is the current price of Axsome Therapeutics, Inc. - Common Stock?
    The current price of Axsome Therapeutics, Inc. - Common Stock is 171.88
    When was Axsome Therapeutics, Inc. - Common Stock last traded?
    The last trade of Axsome Therapeutics, Inc. - Common Stock was at 01/06/26 04:00 PM ET
    What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
    The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.11B
    How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
    Axsome Therapeutics, Inc. - Common Stock has 8B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.